High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival

British Journal of Cancer

Volumn 108, Issue 10, 2013, Pages 2097-2105

  Noble, P ^a   Vyas, M ^a   Al Attar, A ^a   Durrant, S ^a   Scholefield, J ^a   Durrant, L ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD16 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

AGED; APOPTOSIS; CASPASE 3; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STROMAL CELLS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878598990     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.166     Document Type: Article

References (49)

1. Adegboyega PA, Mifflin RC, DiMari JF, Saada JI, Powell DW (2002) Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Lab Med 126(7): 829-836.
2. Balliet RM, Capparelli C, Guido C, Pestell TG, Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Chiavarina B, Pestell RG, Howell A, Sotgia F, Lisanti MP (2011) Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. Cell Cycle 10(23): 4065-4073.
3. Blomgren K, Zhu C, Wang X, Karlsson JO, Leverin AL, Bahr BA, Mallard C, Hagberg H (2001) Synergistic activation of caspase-3 by mm-calpain after neonatal hypoxia-ischemia: a mechanism of 'pathological apoptosis'? J.Biol Chem 276(130): 10191-10198.
4. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21): 7252-7259.
5. Cheong JW, Chong SY, Kim JY, Eom JI, Jeung HK, Maeng HY, Lee ST, Min YH (2003) Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Clin Cancer Res 9(13): 5018-5027.
6. de Heer P, de Bruin EC, Klein-Kranenbarg E, Aalbers RI, Marijnen CA, Putter H, de Bont HJ, Nagelkerke JF, van Krieken JH, Verspaget HW, van de Velde CJ, Kuppen PJ (2007) Caspase-3 activity predicts local recurrence in rectal cancer. Clin Cancer Res 13(19): 5810-5815.
7. Duncan TJ, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG (2007) The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer. World J Surg Oncol 5: 31.
8. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD (2005) A critical function for type I interferons in cancer immunoediting. Nat Immunol 6(7): 722-729.
9. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC (2003) Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52(10): 638-642.
10. Dyer MJ, MacFarlane M, Cohen GM (2007) Barriers to effective TRAILtargeted therapy of malignancy. J Clin Oncol 25(28): 4505-4506.
11. Garnier P, Ying W, Swanson RA (2003) Ischemic preconditioning by caspase cleavage of poly(ADP-ribose) polymerase-1. J Neurosci 23(22): 7967-7973.
12. Giroux M, Schmidt M, Descoteaux A (2003) IFN-gamma-induced MHC class II expression: transactivation of class II transactivator promoter IV by IFN regulatory factor-1 is regulated by protein kinase C-alpha. J Immunol 171(8): 4187-4194.
13. Gown AM, Willingham MC (2002) Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 50(4): 449-454.
14. Gregory CD, Pound JD (2010) Microenvironmental influences of apoptosis in vivo and in vitro. Apoptosis 15(9): 1029-1049.
15. Hector S, Prehn JH (2009) Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta 1795(2): 117-129.
16. Jonges LE, Nagelkerke JF, Ensink NG, van der Velde EA, Tollenaar RA, Fleuren GJ, van de Velde CJ, Morreau H, Kuppen PJ (2001) Caspase-3 activity as a prognostic factor in colorectal carcinoma. Lab Invest 81(5): 681-688.
17. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH, Fleuren GJ (2008) Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 14(7): 2028-2035.
18. Kakar S, Aksoy S, Burgart LJ, Smyrk TC (2004) Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol 17(6): 696-700.
19. Koelink PJ, Sier CF, Hommes DW, Lamers CB, Verspaget HW (2009) Clinical significance of stromal apoptosis in colorectal cancer. Br J Cancer 101(5): 765-773.
20. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7): 844-847.
21. Koornstra JJ, de Jong S, Hollema H, de Vries EG, Kleibeuker JH (2003) Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol 45(1): 37-53.
22. Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Duffy MJ, Schimmer AD, Tsao M, Brown E, Sawyers A, Andreeff M, Mercola D, Krajewski S, Reed JC (2008) Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res 14(10): 3011-3021.
23. Leonardos L, Butler LM, Hewett PJ, Zalewski PD, Cowled PA (1999) The activity of caspase-3-like proteases is elevated during the development of colorectal carcinoma. Cancer Lett 143(1): 29-35.
24. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A, Witkiewicz A, Lin Z, Balliet R, Howell A, Sotgia F (2010) Understanding the 'lethal' drivers of tumor-stroma coevolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther 10(6): 537-542.
25. Mazelin L, Bernet A, Bonod-Bidaud C, Pays L, Arnaud S, Gespach C, Bredesen DE, Scoazec JY, Mehlen P (2004) Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature 431(7004): 80-84.
26. McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I, Trowsdale J, Durrant LG (2009) NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 15(22): 6993-7002.
27. Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, Metzger U, Reuter J, Terracciano L, Herrmann R, Rochlitz C (2002) DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int J Cancer 102(3): 254-257.
28. Nausch N, Cerwenka A (2008) NKG2D ligands in tumor immunity. Oncogene 27(45): 5944-5958.
29. NICE (2004) Improving Outcomes in Colorectal Cancers: Manual Update. National Institute for Clinical Excellence: London, UK.
30. O'Connell J, Bennett MW, Nally K, Houston A, O'Sullivan GC, Shanahan F (2000) Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann N Y Acad Sci 910: 178-192; discussion 193-5.
31. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59(19): 5002-5011.
32. Patel AV, Krimm RF (2010) BDNF is required for the survival of differentiated geniculate ganglion neurons. Dev Biol 340(2): 419-429.
33. Quinn MJBP, Brock A, Kirby EA, Jones J (2001) Cancer Trends in England and Wales, 1950-1999Stationery Office: London, UK 206-207.
34. Sabine VS, Faratian D, Kirkegaard-Clausen T, Bartlett JM (2012) Validation of activated caspase-3 antibody staining as a marker of apoptosis in breast cancer. Histopathology 60(2): 369-371.
35. Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsky P, Jesch B, Heinzl H, Birner P (2012) Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat 134(1): 237-244.
36. Servais C, Erez N (2013) From sentinel cells to inflammatory culprits: cancerassociated fibroblasts in tumour-related inflammation. J Pathol 229(2): 198-207.
37. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18(5): 349-355.
38. Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, Durrant LG (2010) Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 59(7): 926-933.
39. Soung YH, Lee JW, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH (2004) Somatic mutations of CASP3 gene in human cancers. Hum Genet 115(2): 112-115.
40. Thome CH, dos Santos GA, Ferreira GA, Scheucher PS, Izumi C, Leopoldino AM, Simao AM, Ciancaglini P, de Oliveira KT, Chin A, Hanash SM, Falcao RP, Rego EM, Greene LJ, Faca VM (2012) Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity. Mol CellProteomics 11(12): 1898-1912.
41. Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M (2007) Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res 13(7): 2082-2090.
42. Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG (2007) Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 13(17): 5070-5075.
43. Van Meter ME, Kim ES (2010) Bevacizumab: current updates in treatment. Curr Opin Oncol 22(6): 586-591.
44. Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27(45): 5932-5943.
45. Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, Scholefield JH, Durrant LG (2005) Evidence that the p53 negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J Surg Oncol 3: 47.
46. Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG (2006a) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118(1): 6-10.
47. Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, Scholefield JH, Durrant LG (2006b) Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 118(6): 1445-1452.
48. Wen Y, Wang CT, Ma TT, Li ZY, Zhou LN, Mu B, Leng F, Shi HS, Li YO, Wei YQ (2010) Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 101(11): 2325-2332.
49. Yang SY, Sales KM, Fuller B, Seifalian AM, Winslet MC (2009) Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med 15(5): 225-233.